texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Houston Clinical Trials

Texas Oncology cancer centers in Houston participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Houston area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Houston area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Houston area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Houston area and talk to you doctor to determine which clinical trial is right for you.

Prostate Cancer

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase:

Title: A Phase 2 Open-label Extension Study for Subjects WithProstate Cancer Who Previously Participated in anEnzalutamide Clinical Study View

Renal Cancer

Indication: Renal Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRC View

Indication: Renal Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Renal Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Skin Cancer

Indication: Skin Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Skin Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Solid Tumors

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Testicular Cancer

Indication: Testicular Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Thyroid Cancer

Indication: Thyroid Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Urothelial Cancer

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Protocol 42756493BLC2001 A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) (3475-672) View

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Indication: Renal Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Skin Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Deke Slayton Cancer Center

Indication: Skin Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Houston Memorial City

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase:

Title: A Phase 2 Open-label Extension Study for Subjects WithProstate Cancer Who Previously Participated in anEnzalutamide Clinical Study View

Indication: Renal Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRC View

Indication: Renal Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Skin Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Protocol 42756493BLC2001 A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) (3475-672) View

Texas Oncology-Houston Southeast

Indication: Skin Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Sugar Land

Indication: Skin Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-The Woodlands

Indication: Renal Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Skin Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Testicular Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Urothelial Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

No Phase

Indication: Prostate Cancer

Location: Texas Oncology-Houston Memorial City

Phase:

Title: A Phase 2 Open-label Extension Study for Subjects WithProstate Cancer Who Previously Participated in anEnzalutamide Clinical Study View

Phase II

Indication: Skin Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: Protocol 42756493BLC2001 A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Urothelial Cancer

Location: Texas Oncology-Sugar Land

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Deke Slayton Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-The Woodlands

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Indication: Skin Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Southeast

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Phase III

Indication: Renal Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase III Randomized, Open-label, Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRC View

Indication: Renal Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma (MK-3475-361) View

Indication: Urothelial Cancer

Location: Texas Oncology-Houston Memorial City

Phase: III

Title: A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) (3475-672) View

Indication: Renal Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-The Woodlands

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Renal Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Solid Tumors

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Testicular Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Indication: Thyroid Cancer

Location: Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center

Phase: III

Title: Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001) View

Phase IV

Indication: Solid Tumors

Location: Texas Oncology-The Woodlands

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View